Actively Recruiting
Evaluating Intravenous Anifrolumab for Children Aged 5 to 17 with Moderate to Severe Active Systemic Lupus Erythematosus While Receiving Standard Care
Led by AstraZeneca · Updated on 2026-09-30
100
Participants Needed
103
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics, pharmacodynamics, efficacy, and safety of anifrolumab infusion compared with placebo in children aged 5 to under 18 years with moderate to severe active systemic lupus erythematosus SLE who are on standard background therapy. This phase III study aims to better understand how anifrolumab works and its effects in pediatric SLE patients. Participants are randomly assigned to receive either anifrolumab or a matching placebo via intravenous infusion every 4 weeks. The study includes multiple periods a screening period up to 30 days Part A, a four-week double-blind, placebo-controlled pharmacokinetic phase Part B, a double-blind, placebo-controlled safety and efficacy phase lasting 48 to 52 weeks depending on prior participation Part C, a 52-week open-label extension and Part D, a safety follow-up with one visit 12 weeks after the last dose. During the study, participants undergo various assessments including blood tests to measure drug levels, immune markers, and disease activity using specific lupus assessment tools. Researchers monitor response to treatment, safety, and changes in corticosteroid use over time. The total participation lasts about 116 weeks, with scheduled visits for infusions and evaluations to track disease progress and treatment effects.
CONDITIONS
Brief Title
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here